Back to top
more

Codexis (CDXS)

(Delayed Data from NSDQ)

$2.69 USD

2.69
491,217

-0.18 (-6.27%)

Updated Apr 15, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Codexis (CDXS) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Codexis (CDXS) delivered earnings and revenue surprises of 112.50% and 7.42%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Can Low Occupancy Rate Affect Select Medical (SEM) Q4 Earnings?

by Zacks Equity Research

Select Medical's (SEM) fourth-quarter results are likely to reflect growing visits in Outpatient Rehabilitation and Concentra.

ANSYS (ANSS) to Report Q4 Earnings: Here's What to Expect

by Zacks Equity Research

ANSYS' (ANSS) fourth-quarter performance is likely to have benefited from strength in the aerospace and defense, high-tech and automotive sectors.

WIX Set to Report Q4 Earnings: Here's What You Should Know

by Zacks Equity Research

WIX Q4 performance is likely to have benefited from an uptake of new products and improvement in the user base.

Higher Visits to Soften Cost Blow for Teladoc (TDOC) Q4 Earnings

by Zacks Equity Research

Teladoc's (TDOC) fourth-quarter results are likely to reflect growth in BetterHelp's profit levels.

Can Low Patient Days Affect Community Health (CYH) Q4 Earnings?

by Zacks Equity Research

Community Health's (CYH) fourth-quarter results are likely to reflect lower adjusted admissions, declining beds in services and occupancy rate.

Bristol Myers Squibb (BMY) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Bristol Myers (BMY) delivered earnings and revenue surprises of 13.64% and 0.28%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Codexis (CDXS) Transfers Leasing Rights to Vaxcyte, Stock Up

by Zacks Equity Research

Codexis (CDXS) transfers the leasing rights of its San Carlos, CA location to Vaxcyte to focus on technology development, inducing cost savings, to extend its cash runway to mid-2026. The stock rises 7%.

Codexis (CDXS) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Codexis (CDXS) delivered earnings and revenue surprises of 19.05% and 0.84%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Codexis (CDXS) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Codexis (CDXS) delivered earnings and revenue surprises of -17.24% and 11.34%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Will Alimera Sciences (ALIM) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Alimera Sciences (ALIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Codexis (CDXS) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Codexis (CDXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Codexis (CDXS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Codexis (CDXS) delivered earnings and revenue surprises of 17.39% and 4.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

How Much Upside is Left in Codexis (CDXS)? Wall Street Analysts Think 219%

by Zacks Equity Research

The consensus price target hints at a 219.4% upside potential for Codexis (CDXS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Codexis (CDXS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Codexis (CDXS) delivered earnings and revenue surprises of 16.67% and 9.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Codexis (CDXS) delivered earnings and revenue surprises of 71.43% and 1.26%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Horizon Therapeutics (HZNP) Q2 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of -20.74% and 6.65%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Codexis (CDXS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Codexis (CDXS) Surges 9.7%: Is This an Indication of Further Gains?

by Zacks Equity Research

Codexis (CDXS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Codexis (CDXS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Codexis (CDXS) delivered earnings and revenue surprises of 27.78% and 21.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Codexis (CDXS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

After Plunging 39.6% in 4 Weeks, Here's Why the Trend Might Reverse for Codexis (CDXS)

by Zacks Equity Research

Codexis (CDXS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Codexis (CDXS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Codexis (CDXS) delivered earnings and revenue surprises of 11.11% and 1.73%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Codexis (CDXS) Q4 Earnings Expected to Decline

by Zacks Equity Research

Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.